Objectives: Investigation with the crude ethanolic extract of Argyria captiformis leaves was carried out to evaluate its possible thrombolysis and to analyze in –vivo neuro-pharmacological effects as anxiety is a particular form of behavioral inhibition that occurs in response to novel environment events and also phytochemical screening of plant extract. Method: Ethanolic extract of Argyria cap...

SAK-RGD-K2-Hir and SAK-RGD-K2-Hirul are recombinant proteins that are derivatives of r-SAK (recombinant staphylokinase). They are characterized by their fibrin-specific plasminogen activation properties and their antithrombin and antiplatelet activities. The difference between these proteins is the presence of the antithrombotic fragment (hirudin or hirulog) in the C-terminal portion of the r-S...

BACKGROUND DSPA (Desmodus salivary plasminogen activator) is a new thrombolytic agent corresponding to a natural plasminogen activator discovered in the saliva of the vampire bat Desmodus rotundus. Compared with tissue plasminogen activator (TPA), DSPA, produced in a recombinant cell line, is more fibrin cofactor dependent than TPA. METHODS AND RESULTS The thrombolytic properties of DSPA and ...

BACKGROUND The efficacy of fibrinolytic therapy is limited by the small surface area of the clot that is available for the binding of the thrombolytic agent, such as tissue-type plasminogen activator (t-PA). We hypothesized that exposure of the clot to ultrasound during thrombolytic treatment could enhance lysis through perturbation of the thrombus, which would expose additional fibrin binding ...

uring the 1980s, thrombolytic therapy became the initial reatment for patients with acute myocardial infarction AMI). Toward the end of the decade, primary percutaneus coronary intervention (PCI) was shown to be effective 1,2), and a recent analysis of 23 randomized trials demontrated improved rates of reinfarction, stroke, and death ompared with thrombolytic therapy (3). However, because f lim...

OBJECTIVES We sought to assess the efficacy and safety of thrombolytic therapy in patients with an acute pulmonary embolism (PE). BACKGROUND Thrombolytic therapy is approved for the treatment of acute PE; however, the safety and efficacy of this therapy remain debated. METHODS A meta-analysis of randomized, controlled trials comparing thrombolytic agents with intravenous heparin in patients wit...

BACKGROUND The value of thrombolytic therapy in unstable angina is unclear. METHODS AND RESULTS To study this problem, 159 patients were studied in a double-blind, placebo-controlled multicenter trial. Patients without a previous myocardial infarction, with a typical history of unstable angina, and ECG abnormalities indicative of ischemia were included. After baseline angiography, study medic...

BACKGROUND Thrombolytic therapy used in patients with acute myocardial infarction may increase the risk of stroke. Scant information is available from community-based studies. SUMMARY OF REPORT Among 5,635 consecutive patients admitted with acute myocardial infarction to hospitals in Seattle and surrounding suburban King County, Washington, 116 (2.1%) experienced strokes during hospitalizatio...